Personalised mRNA Cancer Vaccine Clears Major Phase 3 Test in Melanoma

An experimental personalised mRNA cancer treatment developed by Moderna and Merck has met key goals in a large Phase 3 melanoma trial, marking an important milestone for efforts to use mRNA technology against cancer.

The treatment, known as intismeran autogene or V940, is designed individually using mutations identified in each patient’s tumour. It is being tested alongside Merck’s immunotherapy Keytruda in people with high-risk melanoma whose tumours have been surgically removed.

Merck and Moderna said the 1,137-patient INTerpath-001 trial met its primary endpoint of recurrence-free survival as well as a key secondary endpoint measuring distant metastasis-free survival. The companies reported statistically significant and clinically meaningful improvements compared with Keytruda alone, with no new safety concerns identified. The companies’ Phase 3 announcement provides the trial details.

Not a conventional preventive vaccine

Unlike vaccines designed to prevent infectious diseases, intismeran is made after a patient develops cancer. Scientists analyse the genetic mutations in an individual tumour and use that information to create an mRNA treatment intended to train the immune system to recognise tumour-specific targets.

The approach is therefore better understood as personalised cancer immunotherapy rather than a universal vaccine that prevents melanoma from developing in the first place.

A milestone, but important questions remain

The result is significant because it is the first positive Phase 3 study of an individualised neoantigen mRNA therapy in cancer. However, the full Phase 3 dataset has not yet been presented publicly, and the treatment would still require regulatory review before routine clinical use.

Independent reporting has therefore stressed both the importance of the result and the need to see detailed data, including longer-term outcomes. National Geographic’s report on the development examines what the result could mean for personalised cancer vaccines, while the companies say detailed findings will be presented at a future medical meeting.

Beyond melanoma

The implications could extend beyond skin cancer. Moderna and Merck are studying intismeran in several tumour types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma. Their broader clinical programme will help determine whether the personalised mRNA approach can work consistently across different cancers.

For now, the melanoma result represents a major clinical test passed rather than an approved cure. The next important steps will be publication of the detailed trial results, regulatory assessment and evidence on how the highly personalised manufacturing process can be delivered at scale.